以岭药业(002603) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 2,522,632,691.84, a decrease of 35.89% compared to CNY 3,934,956,597.43 in the same period last year[4] - Net profit attributable to shareholders was CNY 303,927,918.74, down 74.73% from CNY 1,202,514,384.13 year-on-year[4] - Basic earnings per share decreased to CNY 0.1819, down 74.73% from CNY 0.7198 in the same quarter last year[4] - Net profit for Q1 2024 was CNY 301,919,698.61, a decline of 74.9% compared to CNY 1,201,436,813.41 in Q1 2023[20] - Total operating revenue for Q1 2024 was CNY 2,522,632,691.84, a decrease of 35.9% compared to CNY 3,934,956,597.43 in the same period last year[19] - Total operating costs decreased to CNY 2,163,331,046.01, down 13.1% from CNY 2,489,342,813.62 year-over-year[19] - The company recorded a total comprehensive income of CNY 301,886,529.06, down from CNY 1,201,780,951.73 in Q1 2023[21] Cash Flow - The net cash flow from operating activities was CNY 117,005,271.96, a decline of 70.77% compared to CNY 400,342,932.75 in the previous year[9] - Cash flow from operating activities generated a net amount of CNY 117,005,271.96, significantly lower than CNY 400,342,932.75 in Q1 2023[22] - The net cash flow from investment activities was 77,304,877.73 CNY, a significant improvement compared to a net outflow of -1,464,282,378.84 CNY in the same period last year[23] - Cash inflow from financing activities totaled 480,526,733.33 CNY, compared to 200,000,000.00 CNY in the previous year, marking a 140.26% increase[23] - The net increase in cash and cash equivalents was 264,337,158.28 CNY, contrasting with a decrease of -870,348,487.30 CNY in the first quarter of the previous year[23] - The ending balance of cash and cash equivalents reached 1,110,971,287.76 CNY, up from 940,314,663.85 CNY year-over-year[23] - The company received 400,000,000.00 CNY in borrowings, an increase from 200,000,000.00 CNY in the same quarter last year[23] - Total cash outflow for financing activities was 410,505,105.19 CNY, compared to 6,231,972.99 CNY in the previous year[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 17,128,470,785.54, an increase of 0.88% from CNY 16,979,326,536.89 at the end of the previous year[5] - The total liabilities of the company were CNY 4,884,306,169.96, reflecting a decrease from the previous period[16] - The company reported a total liability of CNY 5,388,589,056.51, a decrease from CNY 5,541,331,336.92 in the previous year[20] - The total current liabilities decreased to CNY 4,285,574,207.76 from CNY 4,446,701,155.56, a reduction of about 3.6%[16] - Non-current assets totaled CNY 10,472,109,702.57, slightly up from CNY 10,435,580,799.21, showing a marginal increase[16] - The total equity attributable to shareholders of the parent company rose to CNY 11,753,617,065.70, compared to CNY 11,449,722,316.51 in the previous year[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 195,905[11] - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., held 31.53% of the shares, totaling 526,775,963 shares[11] Expenses - Research and development expenses increased to CNY 180,592,474.56, up 9.9% from CNY 164,844,076.56 year-over-year[19] - The company reported a significant increase in financial expenses, which rose by 1603.45% to CNY 8,435,692.08 due to decreased interest income[8] Accounting and Auditing - The company did not undergo an audit for the first quarter report[24] - The company has adopted new accounting standards starting from 2024, impacting the financial statements[24]